Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines
Virus-like particles (VLP) spontaneously assemble from viral structural proteins. They are naturally biocompatible and non-infectious. VLP can serve as a platform for many potential vaccine epitopes, display them in a dense repeating array, and elicit antibodies against non-immunogenic substances, i...
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
MDPI AG
2020-04-01
|
| Edice: | Viruses |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/1999-4915/12/5/488 |
| _version_ | 1827717929094873088 |
|---|---|
| author | Jerri C. Caldeira Michael Perrine Federica Pericle Federica Cavallo |
| author_facet | Jerri C. Caldeira Michael Perrine Federica Pericle Federica Cavallo |
| author_sort | Jerri C. Caldeira |
| collection | DOAJ |
| description | Virus-like particles (VLP) spontaneously assemble from viral structural proteins. They are naturally biocompatible and non-infectious. VLP can serve as a platform for many potential vaccine epitopes, display them in a dense repeating array, and elicit antibodies against non-immunogenic substances, including tumor-associated self-antigens. Genetic or chemical conjugation facilitates the multivalent display of a homologous or heterologous epitope. Most VLP range in diameter from 25 to 100 nm and, in most cases, drain freely into the lymphatic vessels and induce antibodies with high titers and affinity without the need for additional adjuvants. VLP administration can be performed using different strategies, regimens, and doses to improve the immunogenicity of the antigen they expose on their surface. This article summarizes the features of VLP and presents them as a relevant platform technology to address not only infectious diseases but also chronic diseases and cancer. |
| first_indexed | 2024-03-10T20:12:13Z |
| format | Article |
| id | doaj.art-3948abfc6bdb4a20b51bad939e6f9f9d |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T20:12:13Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-3948abfc6bdb4a20b51bad939e6f9f9d2023-11-19T22:48:36ZengMDPI AGViruses1999-49152020-04-0112548810.3390/v12050488Virus-Like Particles as an Immunogenic Platform for Cancer VaccinesJerri C. Caldeira0Michael Perrine1Federica Pericle2Federica Cavallo3AgilVax, Inc., Albuquerque, NM 87110, USAAgilVax, Inc., Albuquerque, NM 87110, USABorder Biomedical Research Center, University of Texas at El Paso, El Paso, TX 79968, USADepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10124 Torino, ItalyVirus-like particles (VLP) spontaneously assemble from viral structural proteins. They are naturally biocompatible and non-infectious. VLP can serve as a platform for many potential vaccine epitopes, display them in a dense repeating array, and elicit antibodies against non-immunogenic substances, including tumor-associated self-antigens. Genetic or chemical conjugation facilitates the multivalent display of a homologous or heterologous epitope. Most VLP range in diameter from 25 to 100 nm and, in most cases, drain freely into the lymphatic vessels and induce antibodies with high titers and affinity without the need for additional adjuvants. VLP administration can be performed using different strategies, regimens, and doses to improve the immunogenicity of the antigen they expose on their surface. This article summarizes the features of VLP and presents them as a relevant platform technology to address not only infectious diseases but also chronic diseases and cancer.https://www.mdpi.com/1999-4915/12/5/488virus-like particlesvaccinecancerimmunotherapy |
| spellingShingle | Jerri C. Caldeira Michael Perrine Federica Pericle Federica Cavallo Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines Viruses virus-like particles vaccine cancer immunotherapy |
| title | Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines |
| title_full | Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines |
| title_fullStr | Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines |
| title_full_unstemmed | Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines |
| title_short | Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines |
| title_sort | virus like particles as an immunogenic platform for cancer vaccines |
| topic | virus-like particles vaccine cancer immunotherapy |
| url | https://www.mdpi.com/1999-4915/12/5/488 |
| work_keys_str_mv | AT jerriccaldeira viruslikeparticlesasanimmunogenicplatformforcancervaccines AT michaelperrine viruslikeparticlesasanimmunogenicplatformforcancervaccines AT federicapericle viruslikeparticlesasanimmunogenicplatformforcancervaccines AT federicacavallo viruslikeparticlesasanimmunogenicplatformforcancervaccines |